NO20092417L - Kombinasjon av IAP-inhibitorer og FLT3-inhibitorer - Google Patents

Kombinasjon av IAP-inhibitorer og FLT3-inhibitorer

Info

Publication number
NO20092417L
NO20092417L NO20092417A NO20092417A NO20092417L NO 20092417 L NO20092417 L NO 20092417L NO 20092417 A NO20092417 A NO 20092417A NO 20092417 A NO20092417 A NO 20092417A NO 20092417 L NO20092417 L NO 20092417L
Authority
NO
Norway
Prior art keywords
combination
inhibitors
iap
flt3
active agents
Prior art date
Application number
NO20092417A
Other languages
English (en)
Inventor
Leigh Zawel
James Douglas Griffin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092417L publication Critical patent/NO20092417L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen er relatert til kombinasjoner av IAP-inhibitorer og FLT3-inhibitorer, farmakologiske sammensetninger omfattende nevnte kombinasjon, fremgangsmåter for behandling av hematologiske maligniteter, inkluderende akutt myeloid leukemi (AML), omfattende kombinasjonen av en forbindelse som inhiberer bindingen av den andre mitokondri-deriverte aktivatoren av kaspase (Smac) protein til inhibitor av apoptose (IAP-er) (IAP-inhibitor) og ett eller flere farmasøytisk aktive midler og anvendelsen av disse kombinasjonene for behandlingen av akutt myeloid leukemi; og en kommersiell pakning omfattende nevnte kombinasjon.
NO20092417A 2006-11-28 2009-06-24 Kombinasjon av IAP-inhibitorer og FLT3-inhibitorer NO20092417L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US89108807P 2007-02-22 2007-02-22
PCT/US2007/085579 WO2008067280A2 (en) 2006-11-28 2007-11-27 Combination of iap inhibitors and flt3 inhibitors

Publications (1)

Publication Number Publication Date
NO20092417L true NO20092417L (no) 2009-08-25

Family

ID=39386468

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092417A NO20092417L (no) 2006-11-28 2009-06-24 Kombinasjon av IAP-inhibitorer og FLT3-inhibitorer

Country Status (20)

Country Link
US (1) US8492429B2 (no)
EP (1) EP2089024B1 (no)
JP (1) JP5394249B2 (no)
KR (1) KR20090087094A (no)
AT (1) ATE509629T1 (no)
AU (1) AU2007325280B2 (no)
BR (1) BRPI0719543A2 (no)
CA (1) CA2670498A1 (no)
CO (1) CO6210722A2 (no)
EC (1) ECSP099472A (no)
GT (1) GT200900142A (no)
IL (1) IL198551A0 (no)
MA (1) MA30966B1 (no)
MX (1) MX2009005621A (no)
NO (1) NO20092417L (no)
PL (1) PL2089024T3 (no)
PT (1) PT2089024E (no)
RU (1) RU2456983C2 (no)
TN (1) TN2009000206A1 (no)
WO (1) WO2008067280A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
KR20080067357A (ko) 2005-10-25 2008-07-18 에게라 쎄라퓨틱스 인코포레이티드 Ｉａｐ ｂｉｒ 도메인 결합 화합물
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
BRPI0912692A2 (pt) 2008-05-16 2017-03-21 Dana Farber Cancer Inst Inc imunomodulação através de inibidores de iap
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
EP2760446A1 (en) 2011-09-30 2014-08-06 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
NZ714347A (en) 2013-06-25 2020-01-31 Walter & Eliza Hall Inst Medical Res Method of treating intracellular infection
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
KR20200102949A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
PE20212153A1 (es) 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
MX2021011606A (es) 2019-04-02 2021-12-10 Aligos Therapeutics Inc Compuestos dirigidos a prmt5.
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1453661A1 (ru) * 1972-11-17 1989-10-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Противоопухолевое средство "продимин
AU2003249920A1 (en) 2002-07-02 2004-01-23 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
KR20080083220A (ko) * 2004-04-07 2008-09-16 노파르티스 아게 Ｉａｐ 억제제
ES2684120T3 (es) 2005-12-20 2018-10-01 Novartis Ag Combinación de un inhibidor de IAP y un taxano
PE20110217A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
BRPI0719543A2 (pt) 2014-02-25
KR20090087094A (ko) 2009-08-14
US8492429B2 (en) 2013-07-23
GT200900142A (es) 2010-06-24
AU2007325280B2 (en) 2011-03-10
MX2009005621A (es) 2009-06-12
PL2089024T3 (pl) 2011-10-31
PT2089024E (pt) 2011-08-31
ATE509629T1 (de) 2011-06-15
US20100056467A1 (en) 2010-03-04
EP2089024B1 (en) 2011-05-18
EP2089024A2 (en) 2009-08-19
JP5394249B2 (ja) 2014-01-22
WO2008067280A2 (en) 2008-06-05
AU2007325280A1 (en) 2008-06-05
RU2009124590A (ru) 2011-01-10
CA2670498A1 (en) 2008-06-05
ECSP099472A (es) 2009-10-30
RU2456983C2 (ru) 2012-07-27
WO2008067280A3 (en) 2008-08-07
JP2010511059A (ja) 2010-04-08
MA30966B1 (fr) 2009-12-01
CO6210722A2 (es) 2010-10-20
IL198551A0 (en) 2010-02-17
TN2009000206A1 (en) 2010-10-18

Similar Documents

Publication Publication Date Title
NO20092417L (no) Kombinasjon av IAP-inhibitorer og FLT3-inhibitorer
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2009006877A (es) Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
ZA200701629B (en) Gyrase inhibitors and uses thereof
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
EA200900691A1 (ru) Применение ингибиторов iap для лечения острого миелоидного лейкоза
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
NO20091495L (no) Pyrazolopyrimidinderivat
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
MXPA05006408A (es) Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
HUP0300576A2 (hu) Érkárosító hatású, osztott dózisú gyógyászati készítmény
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
WO2006091222A3 (en) Methods of treating and preventing severe acute respiratory syndrome (sars) with avr118
SI1830833T1 (sl) Kombinacija inhibitorja glicinskega transporterja GlyT in antipsihotika za zdravljenje simptomovshizofrenije in tudi njena priprava in njena uporaba
MXPA04006269A (es) Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application